Leadership

Pierluigi Paracchi

CO-FOUNDER
Chief Executive Officer

Pierluigi Paracchi is an experienced venture capital investor, Founder and CEO of Quantica SGR, Co-founder of Axòn Capital and AurorA Science and previously venture Consultant at Sofinnova Partners. He was also an investor in and Board Member of Ethical Oncology Science, which was acquired in 2013 in a total deal of $400+ million. He also serves as non-executive Director at Altheia Science, non-executive Chairman at Lipogems International (Medical Device for Processing Adipose Tissue).
Pierluigi is a member of the Assobiotec Executive Committee, the Italian Association for the development of biotechnology and a member of the InnovUp Executive Committee, non-profit association representing the Italian innovation chain: startups, scaleups, innovative SMEs, innovation centers, incubators and accelerators.
From 2024 Pierluigi is Moderator of the “Working Table for the Internationalization of Biotechnology Sector” Ministero degli Affari Esteri e della Cooperazione Internazionale.

Carlo Russo, M.D.

Chief Medical Officer
& Head of Development

Carlo Russo is a biotech executive with vast experience in research & development  in large pharma companies, including GSK, Merck and Biotech. He has served as Head of Development of GSK’s R&D Biopharm and Rare Disease Units, the Head of Cardiovascular Metabolic Center and the founder & Head of the Alternative Development Programs. He was Executive VP and CMO of Adverum, CMO & Head R&D of Annapurna and President and CEO of VaxInnate Corporation, among other senior roles. Carlo holds a number of senior positions at research institutions, including Cornell University Medical College, Columbia University and Scripps Research Institute. He holds his MD and Board Certification in Hematology from the University of Genoa Medical School and is the author of more than 70 scientific publications.

Stefania Mazzoleni Ph.D.

Director of Program Development

Stefania Mazzoleni currently serves as Director of Program Development at Genenta where she manages and oversees the scientific development of parallel immuno-gene therapy studies in oncology indications and provides scientific support for Investor interactions, by combining deep pre-clinical and scientific area-specific knowledge to clinical research experience. Stefania has more than 15 years’ experience in life science R&D, oncology and project management, including more than 4 years in drug development and cell & gene therapy from various academic institutions and pharmas. Stefania received a MsC in Medical Biotechnology, holds her Ph.D. in Molecular and Cellular Biology from San Raffaele Vita-Salute University, has a Second level vocational Master’s in Pharmacy and Pharmaceutical Oncology and is a member of the European Academy of Tumor Immunology (EATI).

Luigi Naldini Professor,
Ph.D., M.D.

CO-FOUNDER
Executive Scientific Board Chairman

Luigi Naldini is a renowned scientist and academic, considered as the father of the Lentivirus Gene Therapy. Luigi is Professor of Cell and Tissue Biology and Cell and Gene Therapy at the Vita-Salute San Raffaele University School of Medicine in Milan, and Director of the San Raffaele-Telethon Institute for Gene Therapy and of the Division of Regenerative Medicine, Stem Cells & Gene Therapy at the San Raffaele Scientific Institute. He has previously served as President of the European Society of Gene and Cell Therapy and a member of the Board of Directors and Advisory Council of the American Society of Gene and Cell Therapy. Luigi is also a scientific advisor on EMEA and WHO committees for the evaluation of novel gene transfer medicines and has authored more than 250 scientific publications. He won numerous awards including the Outstanding Achievement Award from the American Society of Gene and Cell Therapy (ASGCT) in 2014 and from ESGCT in 2015, the Beutler Prize from the American Society of Hematology (ASH) in 2017 and in 2019 the Jeantet-Collen Prize for Translational Medicine.
Nominated “Grande Ufficiale” dell’Ordine “Al Merito della Repubblica Italiana”, one of the highest ranking honor in Italy, from the President of the Republic and the Prime Minister of Italy, on December 27th 2019.
Elected “Socio Corrispondente- Classe di Scienze Fisiche, Matematiche e Naturali” at the “Accademia Nazionale dei Lincei”, on July 26th, 2022.

Richard B. Slansky

Chief Financial Officer

Richard Slansky is a senior financial executive with more than 30 years of experience as Chief Financial Officer in various biopharmaceutical diagnostic and life science companies, including Oncosec, Biological Dynamics and Genmark Diagnostics. His experience spans public and private companies, pre-revenue to revenue growth, and commercial healthcare and high technology environments. He has been responsible for strategic vision and oversight of financial and operational teams, organizational leadership and creating maximum stakeholder value. He also serves on the Board of Directors of several private companies, including Nuclear RNA Networks, an early-stage RNA gene transcription therapeutics company.

Barbara Regonini

Finance Director

Barbara Regonini is a highly experienced executive with skills in strategic finance, restructuring and reorganization processes, internal controls and corporate governance systems implementation. Prior to joining Genenta, she was Head of Finance at OAM – Financial Supervisory Authority. She previously held CFO roles and was part of the Supervisory Body ex DLGS 231/01 of a public company in the renewable energy field. Former senior manager at PriceWaterhouseCoopers, she has a significant finance background in the industrial and service field. She has a Master’s degree at the University of Nicosia in Science of Digital Currency, a Degree as Strategic CFO at Harvard Business School, a Master’s degree in Business and Administration at the University of Parma and she is a Chartered Public Accountant and Auditor.

Pin It on Pinterest